Table 1.
Clinical course
| Day of TKI treatment | Clinical event | qPCR BCR/ABL, Blood (IS units) | qPCR BCR/ABL, Marrow (IS units) | T lymphoblasts, Marrow |
|---|---|---|---|---|
| −1 | CML diagnosis confirmed | 44 % | 9 % | |
| 1 | Started imatinib 500 mg daily | |||
| 22 | 58 % | |||
| 25 | 65 % | 1 % | ||
| 29 | 69 % | |||
| 34 | 50 % | |||
| 41 | 67 % | |||
| 49 | Started dasatinib 100 mg daily | 56 % | ||
| 54 | 52 % | 52 % | 0.02 % | |
| 64 | 28 % | |||
| 68 | 22 % | |||
| 92 | 4.3 % |
Timeline of clinical events, BCR-ABL1 transcript levels detected by qPCR in the blood and bone marrow, and percentage of T lymphoblasts in the bone marrow as measured by flow cytometry. Timeline is reported relative to day 1 of treatment with imatinib. TKI tyrosine kinase inhibitor, qPCR quantitative polymerase chain reaction, IS international standard units